Disease

Panic disorder

Late-stage therapeutic development

Also known as panic anxiety syndrome.

Clinical trials

Associated genes

Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate

Key developments

3 clinical trials expected to report results, the earliest in Q2 2027.

Upcoming Milestones

Q2 2027Phase III, Randomized, Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device With Conventional Drug Treatment, Compared to Conventional Drug Treatment Alone, in Adult Patients With Moderate to Severe Generalized Anxiety Disorder
Q3 2027Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety Disorder
Q4 2027Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

Major developments

Major trial resultsHigh impact

A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder

Results posted2026-05-19

Upcoming trial readoutImportant

Phase III, Randomized, Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device With Conventional Drug Treatment, Compared to Conventional Drug Treatment Alone, in Adult Patients With Moderate to Severe Generalized Anxiety Disorder

Results expected Q2 20272026-04-01

Clinical Milestones9View all 9

Results posted 1

2026-05-19A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety DisorderResults posted

Results expected 3

2026-04-01Phase III, Randomized, Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device With Conventional Drug Treatment, Compared to Conventional Drug Treatment Alone, in Adult Patients With Moderate to Severe Generalized Anxiety DisorderResults expected Q2 2027
2026-03-09Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety DisorderResults expected Q3 2027
2025-10-31Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and DepressionResults expected Q4 2027

Recently completed 5

+1 more in the activity timeline below

Activity timeline9

2026-06-30ClinicalSafety and Efficacy of Buagafuran Capsules in the Treatment of Generalized Anxiety Disorder: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Flexible-dose Phase Ⅲ Clinical TrialPrimary completion
2026-05-19ClinicalA Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety DisorderResults posted
2026-04-29ClinicalA Phase 3b, Randomized, Double-blind, 8-week, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Centanafadine Once Daily Extended-release Capsules for the Treatment of Adults With Attention-deficit/Hyperactivity Disorder and Comorbid AnxietyCompleted
2026-04-21ClinicalUS, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-4)Primary completion
2026-04-01ClinicalPhase III, Randomized, Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device With Conventional Drug Treatment, Compared to Conventional Drug Treatment Alone, in Adult Patients With Moderate to Severe Generalized Anxiety DisorderResults expected Q2 2027
2026-03-12ClinicalEfficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia：A Prospective, Double-Blind, Randomized, Placebo-Controlled Clinical TrialCompleted
2026-03-09ClinicalCannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety DisorderResults expected Q3 2027
2025-11-01ClinicalImpact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion. A Randomized Double-blind Controlled Trial.Completed
2025-10-31ClinicalProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and DepressionResults expected Q4 2027

Clinical trials

15 sponsors · 2 new · 3 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

Phase 4 · Recruiting · Laureate Institute for Brain Research, Inc.

An Open-label, Comparative, Randomized, Multicenter Phase IV Clinical Study to Evaluate the Clinical Efficacy and Safety of the Drug Ranquilon, Tablets, 1 mg, in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

Phase 4 · Recruiting · Valenta Pharm JSC

Phase 3 · Recruiting · Psicofarma, S.A. De C.V.

Safety and Efficacy of Buagafuran Capsules in the Treatment of Generalized Anxiety Disorder: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Flexible-dose Phase Ⅲ Clinical Trial

Phase 3 · Recruiting · Beijing Union Pharmaceutical Factory Ltd

Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety Disorder

Phase 3 · Recruiting · Wayne State University

US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-4)

Phase 3 · Active, not recruiting · VistaGen Therapeutics, Inc.

Recruiting

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

Phase 4 · Recruiting · Laureate Institute for Brain Research, Inc.

Phase 4 · Recruiting · Valenta Pharm JSC

Phase 3 · Recruiting · Psicofarma, S.A. De C.V.

Phase 3 · Recruiting · Beijing Union Pharmaceutical Factory Ltd

Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety Disorder

Phase 3 · Recruiting · Wayne State University

Recently completed

A Phase 3b, Randomized, Double-blind, 8-week, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Centanafadine Once Daily Extended-release Capsules for the Treatment of Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety

Phase 3 · Completed · Otsuka Pharmaceutical Development & Commercialization, Inc.

Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia：A Prospective, Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Phase 4 · Completed · Xijing Hospital of Digestive Diseases

A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder

Phase 2/3 · Completed · Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3 · Completed · Bionomics Limited

Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion. A Randomized Double-blind Controlled Trial.

Phase 4 · Completed · Benha University

The Efficacy of Melatonin Patches on Dental Anxiety in Children A Randomized Clinical Trial

Phase 4 · Completed · Ain Shams University

Associated genes

9 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

GABRB30.61 GABRA50.61 SLC6A40.60 GABRG20.60 GABRA60.60 GABRA10.60 GABRB10.60 GABRG30.60 OR13H10.00

Disease biology

8 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Gamma-aminobutyric acid receptor subunit beta-3via GABRB30.61 Gamma-aminobutyric acid receptor subunit alpha-5via GABRA50.61 Sodium-dependent serotonin transportervia SLC6A40.60 Gamma-aminobutyric acid receptor subunit gamma-2via GABRG20.60 Gamma-aminobutyric acid receptor subunit alpha-6via GABRA60.60 Gamma-aminobutyric acid receptor subunit alpha-1via GABRA10.60 Gamma-aminobutyric acid receptor subunit beta-1via GABRB10.60 Gamma-aminobutyric acid receptor subunit gamma-3via GABRG30.60

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.

Synonyms

panic anxiety syndrome

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Related entities are derived from literature co-mention (studied together) — associative, not causal.